Literature DB >> 2681587

Myogenic mechanisms in the control of systemic resistance. Introduction and historical background.

B Folkow1.   

Abstract

This paper surveys the early studies and ideas that led to the development of the Bayliss theory in 1902 of a pressure-dependent myogenic tone in the systemic resistance vessels; this important concept was not experimentally verified until about 50 years later. Studies of the complex interactions between this 'active' intrinsic vascular tone, 'passive' wall distensibility and tissue-produced vasodilator factors gradually led to a better understanding of local circulatory control. Precapillary smooth muscles seem to function almost like 'stretch (and/or tension?) receptors with built-in contractility', where transmural pressure serves as a limited positive feedback and tissue vasodilator factors as a potentially powerful negative feedback. Together, these positive and negative feedback factors automatically adjust blood supply to local tissue needs and also protect the capillary exchange section from undue pressure increases thanks to the ensuing 'functional autoregulation'. Observations in these early studies also led to experimental analyses of what was later called 'structural autoregulation', as a long-term analogue to 'functional autoregulation'. 'Structural autoregulation' is the rapid morphological adaptation of the precapillary resistance vessels in hypertension whereby, by a structurally based inner radius reduction and hypertrophic wall (media) thickening, systemic resistance becomes reset upwards for functional operation at a higher pressure level. Like 'functional autoregulation', 'structural autoregulation' is essentially a local vascular response to pressure changes. Finally, myogenic activity, functional and structural autoregulation may have important cellular mechanisms in common, while 'extrinsic' influences, from nexa-connected endothelial cells and neurohormonal mechanisms for example, are likely to act as important modulators of intrinsic smooth muscle activities.

Entities:  

Mesh:

Year:  1989        PMID: 2681587

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  7 in total

1.  Diameter and flow velocity changes of feline small pulmonary vessels in response to sympathetic nerve stimulation.

Authors:  M Shirai; T Shindo; A Shimouchi; I Ninomiya
Journal:  Pflugers Arch       Date:  1994-12       Impact factor: 3.657

2.  Double deletion of calponin 1 and calponin 2 in mice decreases systemic blood pressure with blunted length-tension response of aortic smooth muscle.

Authors:  Han-Zhong Feng; Hui Wang; Katsuhito Takahashi; J-P Jin
Journal:  J Mol Cell Cardiol       Date:  2019-01-29       Impact factor: 5.000

Review 3.  Cerebral Haemodynamics: Effects of Systemic Arterial Pulsatile Function and Hypertension.

Authors:  Alberto Avolio; Mi Ok Kim; Audrey Adji; Sumudu Gangoda; Bhargava Avadhanam; Isabella Tan; Mark Butlin
Journal:  Curr Hypertens Rep       Date:  2018-03-19       Impact factor: 5.369

4.  Sustained Contraction in Vascular Smooth Muscle by Activation of L-type Ca2+ Channels Does Not Involve Ca2+ Sensitization or Caldesmon.

Authors:  Hillevi K Ets; Chun Y Seow; Robert S Moreland
Journal:  Front Pharmacol       Date:  2016-12-26       Impact factor: 5.810

5.  Reduced central sympathetic activity in Parkinson's disease.

Authors:  Heidrun H Krämer; Gothje Lautenschläger; Michael de Azevedo; Kathrin Doppler; Anne Schänzer; Christoph Best; Wolfgang H Oertel; Iris Reuter; Claudia Sommer; Frank Birklein
Journal:  Brain Behav       Date:  2019-11-05       Impact factor: 2.708

6.  Squeezing the muscle: compression clothing and muscle metabolism during recovery from high intensity exercise.

Authors:  Billy Sperlich; Dennis-Peter Born; Kimmo Kaskinoro; Kari K Kalliokoski; Marko S Laaksonen
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

Review 7.  Molecular mechanisms of renal blood flow autoregulation.

Authors:  Marilyn Burke; Mallikarjuna R Pabbidi; Jerry Farley; Richard J Roman
Journal:  Curr Vasc Pharmacol       Date:  2014       Impact factor: 2.719

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.